Abstract
Tissue engineering and regenerative medicine have been the subject of increasingly intensive research for over 20 years, and there is concern in some quarters over the lack of clinically useful products despite the large sums of money invested. This review provides one perspective on orthopedic applications from a biologist working in academia. It is suggested that the delay in clinical application is not atypical of new, biologically based technologies. Some barriers to progress are acknowledged and discussed, but it is also noted that preclinical studies have identified several promising types of cells, scaffolds, and morphogenetic signals, which, although not optimal, are worth advancing toward human trials to establish a bridgehead in the clinic. Although this transitional technology will be replaced by more sophisticated, subsequent systems, it will perform valuable pioneering functions and facilitate the clinical development of the field. Some strategies for achieving this are suggested.
Original language | English (US) |
---|---|
Pages (from-to) | 437-441 |
Number of pages | 5 |
Journal | Tissue Engineering - Part B: Reviews |
Volume | 17 |
Issue number | 6 |
DOIs | |
State | Published - Dec 1 2011 |
ASJC Scopus subject areas
- Bioengineering
- Biomaterials
- Biochemistry
- Biomedical Engineering